Previous Close | N/A |
Open | N/A |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | N/A - N/A |
52 Week Range | undefined - undefined |
Volume | |
Avg. Volume | N/A |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | 3.36 |
Earnings Date | Jul 25, 2024 - Jul 29, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 184.08 |
AbbVie (ABBV) reachead $170.75 at the closing of the latest trading day, reflecting a -1.15% change compared to its last close.
AbbVie (NYSE: ABBV) today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in adults with advanced Parkinson's disease.
Here, we discuss some reasons why buying Alvotech (ALVO) stock now may turn out to be a prudent move.